Study of the molecular bases for the dynamics and dysfunction of dendritic cell subsets in tumor-bearing host

我们检查了具有迁移到引流淋巴结潜力的肿瘤浸润性DC亚群，并确定了CCR7^+ MHC class II^<hi> tidc作为具有抗原摄取和递呈潜力的淋巴结迁移性DC的前体。趋化因子受体KO （CKO）小鼠和野生型与CKO混合骨髓嵌合体小鼠显示CCR2部分介导tidc的积累。我们还发现tidc在体内对抗癌药物具有相对的耐药性。基于这些结果，我们期望抗癌药物和CCR2靶向药物联合治疗增加tidc将提供一种新的抗癌免疫治疗方法。

We examined the tumor-infiltrating DC subsets with the potential to migrate to draining-lymph nodes and identified CCR7^+ MHC class II^<hi> TIDCs as the precursor of lymph node migratory DCs with antigen uptake and presentation potential. Chemokine receptor KO (CKO) mice and the wild type vs CKO mixed bone marrow chimera mice revealed that CCR2 partially mediates the accumulation of the TIDCs. We also found that the TIDCs were relatively resistant to the anti-cancer drug in vivo. Based on these results, we expect that the combination therapy of anti-cancer drug and CCR2 targeted drug that augment TIDCs would provide a novel anti-cancer immunotherapy.